Piergiacomo C. P.
- Country
- Italy
- Department
- Dermatology
Research Overview
- Effisayil® REP: An open-label, multicenter, single-arm, post-marketing trial (in select countries) to evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab i.v. in treatment of patients with Generalized Pustular Psoriasis (GPP) presenting with a recurrent flare following their initial GPP flare treatment with spesolimab i.v.
- Phase 3 Study of Patidegib Gel 2% for Basal Cell Carcinoma Reduction in Gorlin Syndrome Patients
- Efficacy and Safety Evaluation of Povorcitinib in Adult Patients with Nonsegmental Vitiligo: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 72 of 228 partner sites.
Specializations
Autoimmune Skin Conditions
Specializes in investigating novel treatments for cutaneous lupus erythematosus, including both subacute and chronic forms. Has extensive experience with innovative therapies such as litifilimab and anifrolumab for managing lupus-related skin manifestations.
- Subacute Cutaneous Lupus
- Chronic Cutaneous Lupus
- Bullous Pemphigoid
Inflammatory Skin Disorders
Focuses on treating chronic inflammatory conditions including hidradenitis suppurativa and plaque psoriasis. Investigates advanced therapeutic options including sonelokimab and novel compounds for moderate to severe cases.
- Moderate to Severe Hidradenitis Suppurativa
- Plaque Psoriasis Management
- Atopic Dermatitis
Dermatologic Oncology
Conducts research in skin cancer prevention and treatment, particularly focusing on actinic keratosis and conditions related to Gorlin syndrome. Studies topical interventions for precancerous lesions and basal cell carcinoma prevention.
- Basal Cell Carcinoma Prevention
- Actinic Keratosis Management
- Vitiligo Treatment Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.